AI Engines For more Details: Perplexity Kagi Labs You
Blood Pressure Reduction: Penbutolol sulfate works by blocking the action of certain hormones like adrenaline (epinephrine) on the heart and blood vessels. This results in decreased heart rate and relaxation of blood vessels, leading to lower blood pressure.
Management of Angina: By reducing the workload of the heart and improving blood flow to the heart muscle, penbutolol sulfate can help relieve symptoms of angina, such as chest pain or discomfort.
Heart Rhythm Control: Penbutolol sulfate may also help in controlling abnormal heart rhythms (arrhythmias) by stabilizing the heart's electrical activity.
Side Effects: Common side effects of penbutolol sulfate may include dizziness, fatigue, weakness, nausea, stomach upset, diarrhea, and headache. These side effects are often mild and transient, but if they persist or worsen, it's important to inform your healthcare provider.
Bradycardia (Slow Heart Rate): Since penbutolol sulfate decreases heart rate, it can sometimes lead to bradycardia, especially in individuals with preexisting heart conditions. Symptoms of bradycardia may include fainting, dizziness, fatigue, and shortness of breath. Notify your healthcare provider if you experience these symptoms.
Masking Symptoms of Hypoglycemia: Beta-blockers like penbutolol sulfate can mask some of the signs and symptoms of hypoglycemia (low blood sugar), such as rapid heartbeat and trembling. This may be problematic for individuals with diabetes who rely on these symptoms to recognize low blood sugar levels.
Asthma and COPD: Beta-blockers can potentially worsen respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD) by narrowing the airways. Penbutolol sulfate should be used with caution in individuals with these conditions and may be contraindicated in some cases.
Fatigue and Exercise Tolerance: Some individuals may experience fatigue or reduced exercise tolerance while taking penbutolol sulfate. This can affect physical activities and performance, so it's essential to discuss any changes in activity level with your healthcare provider.
Interactions with Other Medications: Penbutolol sulfate can interact with other medications, including other blood pressure-lowering drugs, certain antidepressants, and medications for diabetes. It's important to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.
Withdrawal: Abruptly stopping penbutolol sulfate can lead to rebound hypertension or worsening of heart conditions. If discontinuation is necessary, it should be done gradually under the guidance of a healthcare professional.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Faecalibacterium prausnitzii | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Butyrivibrio | genus | Decreases |
| 0 | 1 | Christensenella | genus | Decreases |
| 0 | 1 | Komagataeibacter | genus | Decreases |
| 0 | 1 | Maliibacterium | genus | Decreases |
| 0 | 1 | Wujia | genus | Decreases |
| 0 | 1 | Simiaoa | genus | Decreases |
| 0 | 1 | Subdoligranulum | genus | Decreases |
| 0 | 1 | Vescimonas | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Novisyntrophococcus | genus | Decreases |
| 0 | 1 | Anaerobutyricum | genus | Decreases |
| 0 | 1 | Pseudobutyrivibrio | genus | Decreases |
| 0 | 1 | Acutalibacter | genus | Decreases |
| 0 | 1 | Wansuia | genus | Decreases |
| 0 | 1 | Qiania | genus | Decreases |
| 0 | 1 | Mageeibacillus | genus | Decreases |
| 0 | 1 | Eubacterium | genus | Decreases |
| 0 | 1 | Intestinimonas | genus | Decreases |
| 0 | 1 | Ligilactobacillus | genus | Decreases |
| 0 | 1 | Catenibacterium | genus | Decreases |
| 0 | 1 | Solibaculum | genus | Decreases |
| 0 | 1 | Oscillibacter | genus | Decreases |
| 0 | 1 | Anaerotruncus | genus | Decreases |
| 0 | 1 | Faecalitalea | genus | Decreases |
| 0 | 1 | Monoglobus | genus | Decreases |
| 0 | 1 | Intestinibaculum | genus | Decreases |
| 0 | 1 | Treponema | genus | Decreases |
| 0 | 1 | Lawsonibacter | genus | Decreases |
| 0 | 1 | Longicatena | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Faecalibacterium | genus | Decreases |
| 0 | 1 | Pusillibacter | genus | Decreases |
| 0 | 1 | Massilistercora | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Ruthenibacterium | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
| 0 | 1 | Butyrivibrio crossotus | species | Decreases |
| 0 | 1 | Simiaoa sunii | species | Decreases |
| 0 | 1 | Wujia chipingensis | species | Decreases |
| 0 | 1 | Eubacterium sp. MSJ-33 | species | Decreases |
| 0 | 1 | Roseburia rectibacter | species | Decreases |
| 0 | 1 | Roseburia hominis | species | Decreases |
| 0 | 1 | Streptococcus vestibularis | species | Decreases |
| 0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
| 0 | 1 | Coprococcus eutactus | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I3-3-33 | species | Decreases |
| 0 | 1 | Roseburia intestinalis | species | Decreases |
| 0 | 1 | Streptococcus parasanguinis | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I4-1-79 | species | Decreases |
| 0 | 1 | Faecalibacterium sp. IP-1-18 | species | Decreases |
| 0 | 1 | Streptococcus sp. LPB0220 | species | Decreases |
| 0 | 1 | Streptococcus sp. HSISM1 | species | Decreases |
| 0 | 1 | Ruminococcus bicirculans (ex Wegman et al. 2014) | species | Decreases |
| 0 | 1 | Coprococcus sp. ART55/1 | species | Decreases |
| 0 | 1 | Vescimonas fastidiosa | species | Decreases |
| 0 | 1 | Eubacterium ventriosum | species | Decreases |
| 0 | 1 | [Ruminococcus] lactaris | species | Decreases |
| 0 | 1 | Ligilactobacillus ruminis | species | Decreases |
| 0 | 1 | Faecalibacterium sp. HTF-F | species | Decreases |
| 0 | 1 | Faecalibacterium duncaniae | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 0 | 1 | Catenibacterium sp. co_0103 | species | Decreases |
| 0 | 1 | Clostridium sp. SY8519 | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I3-3-89 | species | Decreases |
| 0 | 1 | Ruminococcus champanellensis | species | Decreases |
| 0 | 1 | Clostridium sp. M62/1 | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I2-3-92 | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I4-3-84 | species | Decreases |
| 0 | 1 | Faecalibacterium sp. IP-3-29 | species | Decreases |
| 0 | 1 | Vescimonas coprocola | species | Decreases |
| 0 | 1 | Coprococcus comes | species | Decreases |
| 0 | 1 | Faecalibacterium prausnitzii | species | Decreases |
| 0 | 1 | Streptococcus gordonii | species | Decreases |
| 0 | 1 | Intestinimonas butyriciproducens | species | Decreases |
| 0 | 1 | Subdoligranulum variabile | species | Decreases |
| 0 | 1 | Streptococcus sp. oral taxon 061 | species | Decreases |
| 0 | 1 | Intestinibaculum porci | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 0 | 1 | Catenibacterium mitsuokai | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | 0 |
| ADHD | 1.3 | 0.6 | 1.17 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.1 | 3 |
| Allergic Rhinitis (Hay Fever) | 0.4 | 0.8 | -1 |
| Allergies | 0.9 | 1.7 | -0.89 |
| Allergy to milk products | 1 | 0.2 | 4 |
| Alopecia (Hair Loss) | 0.3 | 0.1 | 2 |
| Alzheimer's disease | 1.4 | 3.3 | -1.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.5 | 0.6 | 1.5 |
| Ankylosing spondylitis | 1.2 | 1.1 | 0.09 |
| Anorexia Nervosa | 0.8 | 2.1 | -1.63 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 1.5 | 0.7 | 1.14 |
| Atherosclerosis | 0.7 | 0.5 | 0.4 |
| Atrial fibrillation | 2 | 1.1 | 0.82 |
| Autism | 1.5 | 3.6 | -1.4 |
| Autoimmune Disease | 0.2 | 0.2 | 0 |
| Barrett esophagus cancer | 0.2 | -0.2 | |
| benign prostatic hyperplasia | 0.1 | -0.1 | |
| Biofilm | 0.4 | 0.4 | |
| Bipolar Disorder | 0.9 | 0.9 | 0 |
| Brain Trauma | 0.3 | 1 | -2.33 |
| Cancer (General) | 0.2 | -0.2 | |
| Carcinoma | 1.5 | 1.3 | 0.15 |
| Celiac Disease | 0.5 | 1.5 | -2 |
| Cerebral Palsy | 0.3 | 0.7 | -1.33 |
| Chronic Fatigue Syndrome | 1.6 | 2.2 | -0.38 |
| Chronic Kidney Disease | 0.5 | 2 | -3 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.1 | 0.18 |
| Chronic Urticaria (Hives) | 0.2 | 0.3 | -0.5 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 1.4 | -2.5 |
| Cognitive Function | 1.3 | 0.7 | 0.86 |
| Colorectal Cancer | 1.9 | 0.8 | 1.37 |
| Constipation | 1 | 0.2 | 4 |
| Coronary artery disease | 1.3 | 1.5 | -0.15 |
| COVID-19 | 1.1 | 4.7 | -3.27 |
| Crohn's Disease | 2.2 | 3.8 | -0.73 |
| cystic fibrosis | 0.2 | -0.2 | |
| deep vein thrombosis | 0.3 | 1.4 | -3.67 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 2.9 | 4.4 | -0.52 |
| Dermatomyositis | 0.2 | 0.1 | 1 |
| Eczema | 0.4 | 0.8 | -1 |
| Endometriosis | 1 | 1.3 | -0.3 |
| Eosinophilic Esophagitis | 0.2 | -0.2 | |
| Epilepsy | 0.6 | 0.4 | 0.5 |
| erectile dysfunction | 0.1 | 0.1 | |
| Fibromyalgia | 0.5 | 0.6 | -0.2 |
| Functional constipation / chronic idiopathic constipation | 2.1 | 1.3 | 0.62 |
| gallstone disease (gsd) | 0.9 | 0.4 | 1.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.7 | -6 |
| Generalized anxiety disorder | 0.4 | 0.6 | -0.5 |
| Glioblastoma | 0.1 | 0.3 | -2 |
| Gout | 0.7 | 0.1 | 6 |
| Graves' disease | 0.5 | 1.1 | -1.2 |
| Gulf War Syndrome | 0.4 | 0.4 | |
| Halitosis | 0.4 | 0.2 | 1 |
| Hashimoto's thyroiditis | 1 | 0.9 | 0.11 |
| Heart Failure | 2 | 1.9 | 0.05 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.7 | 0.7 | |
| High Histamine/low DAO | 0.1 | 0.6 | -5 |
| hypercholesterolemia (High Cholesterol) | 0.1 | -0.1 | |
| hyperglycemia | 0.6 | 0.2 | 2 |
| Hyperlipidemia (High Blood Fats) | 0.2 | 0.1 | 1 |
| hypertension (High Blood Pressure | 2 | 2.5 | -0.25 |
| Hypothyroidism | 0.3 | 0.7 | -1.33 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.9 | 1.1 | -0.22 |
| Inflammatory Bowel Disease | 1.6 | 4 | -1.5 |
| Insomnia | 1.1 | 1.8 | -0.64 |
| Intelligence | 0.1 | 0.6 | -5 |
| Intracranial aneurysms | 0.8 | 0.4 | 1 |
| Irritable Bowel Syndrome | 1.6 | 2.1 | -0.31 |
| ischemic stroke | 0.8 | 0.8 | 0 |
| Juvenile idiopathic arthritis | 0.1 | -0.1 | |
| Liver Cirrhosis | 2.8 | 1.7 | 0.65 |
| Long COVID | 2 | 4.5 | -1.25 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.1 | 0.7 | -6 |
| Mast Cell Issues / mastitis | 0.2 | 0.6 | -2 |
| ME/CFS with IBS | 0.2 | 0.4 | -1 |
| ME/CFS without IBS | 0.2 | 0.3 | -0.5 |
| membranous nephropathy | 0.2 | 0.2 | |
| Menopause | 0.4 | 0.2 | 1 |
| Metabolic Syndrome | 2.4 | 2.3 | 0.04 |
| Mood Disorders | 3 | 3.3 | -0.1 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 1.6 | 2.6 | -0.63 |
| Multiple system atrophy (MSA) | 0.3 | 0.5 | -0.67 |
| myasthenia gravis | 0.3 | 0.4 | -0.33 |
| neuropathic pain | 1 | -1 | |
| Neuropathy (all types) | 0.4 | 0.3 | 0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.1 | 1 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | 2.7 | -0.5 |
| NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
| Obesity | 3.3 | 3.6 | -0.09 |
| obsessive-compulsive disorder | 1.7 | 1.2 | 0.42 |
| Osteoarthritis | 0.3 | 1.2 | -3 |
| Osteoporosis | 0.7 | 0.6 | 0.17 |
| pancreatic cancer | 0.2 | 0.2 | 0 |
| Parkinson's Disease | 2.3 | 3.6 | -0.57 |
| Polycystic ovary syndrome | 2.2 | 1.5 | 0.47 |
| Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
| Premenstrual dysphoric disorder | 0.1 | -0.1 | |
| primary biliary cholangitis | 0.4 | 0.3 | 0.33 |
| Primary sclerosing cholangitis | 0.4 | 1.1 | -1.75 |
| Psoriasis | 0.8 | 1.4 | -0.75 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 1.4 | 1.14 |
| Rosacea | 0.5 | 0.3 | 0.67 |
| Schizophrenia | 1.8 | 1.6 | 0.13 |
| scoliosis | 0.4 | 1.1 | -1.75 |
| sensorineural hearing loss | 0.1 | -0.1 | |
| Sjögren syndrome | 0.7 | 0.9 | -0.29 |
| Sleep Apnea | 1 | 0.4 | 1.5 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
| Stress / posttraumatic stress disorder | 0.5 | 0.5 | 0 |
| Systemic Lupus Erythematosus | 0.6 | 1.3 | -1.17 |
| Tic Disorder | 0.8 | 0.5 | 0.6 |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.9 | 1.8 | -1 |
| Type 2 Diabetes | 2.8 | 2.1 | 0.33 |
| Ulcerative colitis | 1.7 | 1.7 | 0 |
| Unhealthy Ageing | 0.5 | 1.4 | -1.8 |
| Vitiligo | 1.4 | 0.2 | 6 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
